NASDAQ:SNY 15 December 2025 - 15 July 2026

Sanofi stock is under pressure on December 15, 2025, after the French drugmaker disclosed two setbacks tied to its experimental multiple sclerosis medicine tolebrutinib—a regulatory delay in the U.S. for one progressive MS form and a failed Phase 3 endpoint in another. The update pushed Sanofi shares down about 4% in Paris trading, as investors recalibrated expectations for one of the company’s closely watched late-stage pipeline assets. Reuters+1